Get started
Author

Lars Blumenstein

Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
2018 · Dejan Juric, Jordi Rodon, et al. · Journal of Clinical Oncology · 433
Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer
2018 · Dejan Juric, Filip Janku, et al. · JAMA Oncology · 246
PDF
Alternative Splicing of Rac1 Generates Rac1b, a Self-activating GTPase
2004 · Dennis Fiegen, Lars-Christian Haeusler, et al. · Journal of Biological Chemistry · 148
PDF
Structural Insights into the Interaction of ROCKI with the Switch Regions of RhoA
2004 · Radovan Dvorsky, Lars Blumenstein, et al. · Journal of Biological Chemistry · 142
Renal and Multiorgan Safety of 177 Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy
2023 · Ken Herrmann, Kambiz Rahbar, et al. · Journal of Nuclear Medicine · 75
PDF
Comparative functional analysis of the Rac GTPases
2003 · Lars Christian Haeusler, Lars Blumenstein, et al. · FEBS Letters · 75
PDF
Models of the Cooperative Mechanism for Rho Effector Recognition
2004 · Lars Blumenstein, Mohammad Reza Ahmadian · Journal of Biological Chemistry · 73
PDF
Allosteric Regulation of Substrate Channeling in Tryptophan Synthase: Modulation of the l -Serine Reaction in Stage I of the β-Reaction by α-Site Ligands,
2007 · Huu Ngo, Novelle Kimmich, et al. · Biochemistry · 65
Physiologically Based Biopharmaceutics Modeling to Demonstrate Virtual Bioequivalence and Bioequivalence Safe-space for Ribociclib which has Permeation Rate-controlled Absorption
2021 · Marc Laisney, Tycho Heimbach, et al. · Journal of Pharmaceutical Sciences · 55
Synthesis and Characterization of Allosteric Probes of Substrate Channeling in the Tryptophan Synthase Bienzyme Complex,
2007 · Huu Ngo, Rodney Harris, et al. · Biochemistry · 54
Structure and Mechanistic Implications of a Tryptophan Synthase Quinonoid Intermediate
2008 · Thomas R. M. Barends, Tatiana Domratcheva, et al. · ChemBioChem · 48
Absorption, distribution, metabolism, and excretion of [14C]BYL719 (alpelisib) in healthy male volunteers
2015 · Alexander James, Lars Blumenstein, et al. · Cancer Chemotherapy and Pharmacology · 43
Inactivation and activation of Ras by the neurotrophin receptor p75
2004 · Andrea Blöchl, Lars Blumenstein, et al. · European Journal of Neuroscience · 36
PDF
Crystal structure of Rnd3/RhoE: functional implications1
2002 · Dennis Fiegen, Lars Blumenstein, et al. · FEBS Letters · 36
PDF
Purification and Biochemical Properties of Rac1, 2, 3 and the Splice Variant Rac1b
2006 · Lars Christian Haeusler, Lars Hemsath, et al. · Methods in enzymology on CD-ROM/Methods in enzymology · 30
βQ114N and βT110V Mutations Reveal a Critically Important Role of the Substrate α-Carboxylate Site in the Reaction Specificity of Tryptophan Synthase
2007 · Lars Blumenstein, Tatiana Domratcheva, et al. · Biochemistry · 26
Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study
2021 · Giuseppe Curigliano, Miguel Martin, et al. · European Journal of Cancer · 25
Physiologically Based Pharmacokinetic Modeling of Oral Absorption, pH, and Food Effect in Healthy Volunteers to Drive Alpelisib Formulation Selection
2020 · Monika Gajewska, Lars Blumenstein, et al. · The AAPS Journal · 24
Phase lb/ll study of the PI3Kα inhibitor BYL719 in combination with cetuximab in recurrent/metastatic squamous cell cancer of the head and neck (SCCHN).
2014 · Albiruni R. A. Razak, Myung-Ju Ahn, et al. · Journal of Clinical Oncology · 23
Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study
2025 · Mark N. Gaze, Daria Handkiewicz-Junak, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 22
Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study.
2022 · Ken Herrmann, Kambiz Rahbar, et al. · Journal of Clinical Oncology · 20
Abstract PD5-5: Phase I study of the PI3Kα inhibitor BYL719 plus fulvestrant in patients with PIK3CA-altered and wild type ER+/HER2- locally advanced or metastatic breast cancer
2015 · Filip Janku, Dejan Juric, et al. · Cancer Research · 17
A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
2023 · Albiruni R. Abdul Razak, Hung-Ming Wang, et al. · Targeted Oncology · 16
PDF
Tumor dosimetry of [177Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: Results from the VISION trial sub-study.
2023 · Bernd J. Krause, Kim N. Chi, et al. · Journal of Clinical Oncology · 11
Phase I Study of the Pi3K&Agr; Inhibitor Byl719, As a Single Agent in Patients with Advanced Solid Tumors (Ast)
2014 · D. Juric, H. Burris, et al. · Annals of Oncology · 11
Works count: 82
Citation count: 1,815
H-index: 20
I10-index: 28
Year
Topic
Type